<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="212694">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317473</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 1030</org_study_id>
    <secondary_id>HSRRB Log No. A-12094</secondary_id>
    <secondary_id>KEMRI SSC No. 761</secondary_id>
    <secondary_id>HSPC No. HS171</secondary_id>
    <nct_id>NCT00317473</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children</brief_title>
  <official_title>Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>The PATH Malaria Vaccine Initiative (MVI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in
      malaria-exposed children living in western Kenya and aged 12-47 months
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited symptoms during a 7 day follow-up period after each vaccination (5 visits: day of vaccination and days 1, 2, 3, and 7)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited symptoms during a 30 day follow-up period after each vaccination (day of vaccination and the 29 subsequent days)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events during an 8 month follow-up period following the first dose of study vaccine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody responses to MSP-1 by ELISA following immunization with the study vaccine through 364 days following the first dose of study vaccine</measure>
  </secondary_outcome>
  <enrollment>135</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSP-1 (FMP-1) with AS02A vs Imovax rabies vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male or female child, 12 to 47 months of age at the time of screening.

          -  Written informed consent obtained from at least one parent before study start.

          -  Available to participate for the duration of the study (12 months).

        Exclusion Criteria:

          -  Acute disease at the time of entry into the study

          -  Axillary temperature of 37.5 degrees C

          -  Respiratory rate 50

          -  Serum ALT 45 IU/l (i.e., &gt; 1.5 X ULN)

          -  Decreased renal function: serum creatinine levels &gt; 92.2 mM/l (&gt; 1.1 mg/dl).

          -  Significant anemia (Hgb &lt;8 gm/dL).

          -  Thrombocytopenia (Platelets &lt; 100,000 per mm3)

          -  Impaired immunity: (Absolute lymphocyte count [ALC] for 1 year olds &lt; 4.0 x 103/mm3;
             for 2 year olds &lt; 3.0 x 103/mm3; for 3 year olds &lt; 2.0 103/mm3.

          -  History of homozygous sickle cell disease (SS).

          -  Malnutrition (Z score; Malnutrition = Weight for height &lt; - 3 z scores)

          -  Blood transfusion or use of blood-based product in previous 6 months.

          -  Prior receipt of a rabies vaccine or an investigational malaria vaccine.

          -  Use of any investigational drug or vaccine other than the study vaccine within 30
             days preceding the first dose of study vaccine, or planned use up to 30 days after
             the third dose.

          -  Administration of chronic (defined as more than 14 days) immunosuppressants or other
             immune-modifying drugs within six months of vaccination. (For cortico-steroids, this
             will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day. Inhaled
             and topical steroids are allowed).

          -  Administration or anticipated administration of a vaccine not foreseen by the study
             protocol within 30 days of the first dose of vaccine(s) with the exception of tetanus
             toxoid.

          -  Previous vaccination with a vaccine containing MPL or QS21 (e.g., RTS,S).

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection. (No HIV testing will be undertaken as
             part of this study.)

          -  History of allergic reactions or anaphylaxis to immunizations or to any vaccine
             components.

          -  History of surgical splenectomy.

          -  Administration of immunoglobulins or any blood products within the 3 months preceding
             the first dose of study vaccine or planned administration during the study period.

          -  Simultaneous participation in any other clinical trial.

          -  Acute or chronic cardiovascular, pulmonary, hepatic or renal condition, which in the
             opinion of the PI may increase the risk to the subject from participating in the
             study.

          -  Any other condition or circumstance that in the opinion of the investigator may pose
             a threat to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>47 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Withers, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>USAMRU-K</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Project Kombewa Clinic</name>
      <address>
        <city>Kombewa</city>
        <state>Nyanza Province</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine. 2004 Sep 28;22(29-30):3831-40.</citation>
    <PMID>15364429</PMID>
  </reference>
  <reference>
    <citation>Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG; MSP-1 Working Group.. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine. 2006 Apr 5;24(15):3009-17. Epub 2005 Nov 28.</citation>
    <PMID>16356603</PMID>
  </reference>
  <reference>
    <citation>Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG Jr; MSP-1 Malaria Vaccine Working Group.. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine. 2007 Jan 2;25(1):176-84. Epub 2005 Dec 7.</citation>
    <PMID>16388879</PMID>
  </reference>
  <results_reference>
    <citation>Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA. Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. Mol Biochem Parasitol. 2003 May;128(2):195-204.</citation>
    <PMID>12742586</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 19, 2016</lastchanged_date>
  <firstreceived_date>April 20, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>Malaria</keyword>
  <keyword>Merozoite surface protein-1</keyword>
  <keyword>MSP-1</keyword>
  <keyword>Falciparum malaria protein 1</keyword>
  <keyword>FMP-1</keyword>
  <keyword>AS02A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
